Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
Details
Publication Year 2024-03,Volume 65,Issue #3,Page 323-332
Journal Title
Leukemia & Lymphoma
Publication Type
Research article
Abstract
Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment of adults with relapsed or refractory follicular lymphoma (r/r FL). This study used individual patient data from ELARA (tisa-cel) and aggregate published patient data from ZUMA-5 (axi-cel) to compare efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methods. After adjustment for baseline differences in the trial populations, the results suggested that tisa-cel (n = 52), compared with axi-cel (n = 86), had similar effects on overall response rate (91.2% vs. 94.2%; p = .58), complete response rate (74.0% vs. 79.1%; p = .60), progression-free survival (HR [95% CI]: 0.8 [0.4, 1.9]; p = .67), and overall survival (HR [95% CI]: 0.5 [0.2, 1.5]; p = .21). Tisa-cel (n = 53) was associated with better safety outcomes than axi-cel (n = 124), reflected by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.
Publisher
Taylor & Francis
Keywords
Adult; Humans; *Lymphoma, Follicular/therapy; Immunotherapy, Adoptive/adverse effects; *Biological Products/adverse effects; Cytokine Release Syndrome; *Lymphoma, Large B-Cell, Diffuse; Antigens, CD19/adverse effects; *Receptors, Antigen, T-Cell; Relapsed/refractory follicular lymphoma; axicabtagene ciloleucel; matching-adjusted indirect comparison; tisagenlecleucel
Department(s)
Clinical Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-03-05 04:47:26
Last Modified: 2024-03-05 04:47:58

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙